HK Stock Market Move | JUNSHI BIO (01877) falls over 3%; net loss attributable to shareholders for the first three quarters narrows 75% year-on-year; first patient dosed in JS207-017-III-HCC study

JUNSHI BIO (01877) fell over 3%, down 3.21% as of press time at HK$15.37, with turnover of HK$25.338 million. On the news front, on October 29, JUNSHI BIO announced that for the first three quarters of 2026, operating revenue was RMB2.513 billion, up 39.18% year-on-year; net loss attributable to shareholders of the listed company was RMB149 million, narrowing 75% year-on-year; basic loss per share was RMB0.15. In addition, JUNSHI BIO announced that recently, the company's product recombinant humanized anti-PD-1 and VEGF bispecific antibody (code: JS207) combined with recombinant humanized anti-CTLA4 monoclonal antibody (code: JS007) versus toripalimab combined with bevacizumab for first-line treatment of advanced hepatocellular carcinoma a multicenter, randomized, controlled, open-label Phase III clinical study (hereinafter referred to as the "JS207-017-III-HCC study", NCT07823348) has completed dosing of the first patient. This study is the first domestic registrational clinical study of JS207.